Evidence map›Paper›PMID 29137406›Full record

ArticleOncotarget2017

The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia.

Emiliano Fabiani, Giulia Falconi, Nélida Inés Noguera, Ernestina Saulle, Laura Cicconi, Mariadomenica Divona, Cristina Banella, Alessandra Picardi, Anna Maria Cerio, Letizia Boe and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Emiliano Fabiani *Università di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, Italy.
Giulia Falconi *Università di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, Italy.
Nélida Inés NogueraUniversità di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, Italy.
Ernestina SaulleIstituto Superiore di Sanità, Centro Nazionale per la Ricerca e la Valutazione Preclinica e Clinica dei Farmaci, Rome, Italy.
Laura CicconiUniversità di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, Italy.
Mariadomenica DivonaUniversità di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, Italy.
Cristina BanellaFondazione Santa Lucia, Laboratorio di Neuro-Oncoematologia, Rome, Italy.
Alessandra PicardiUniversità di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, Italy.
Anna Maria CerioIstituto Superiore di Sanità, Dipartimento di Ematologia ed Oncologia, Rome, Italy.
Letizia BoeIstituto Superiore di Sanità, Grandi Strumentazioni e Core Facilities, Rome, Italy.
Massimo SanchezIstituto Superiore di Sanità, Grandi Strumentazioni e Core Facilities, Rome, Italy.
Elvira PelosiIstituto Superiore di Sanità, Dipartimento di Ematologia ed Oncologia, Rome, Italy.
Ugo TestaIstituto Superiore di Sanità, Dipartimento di Ematologia ed Oncologia, Rome, Italy.
Francesco Lo-CocoUniversità di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, Italy.
Maria Teresa VosoUniversità di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, Rome, Italy.
Istituto Superiore di Sanità · ITUniversity of Rome Tor Vergata · ITFondazione Santa Lucia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Forkhead box (FOX) genes encode transcription factors, which regulate embryogenesis and play an important role in hematopoietic differentiation and in mesenchymal niche maintenance. Overexpression of the family member FOXC1 has been reported in solid tumors and acute myeloid leukemia (AML). We studied FOXC1 expression and function in acute promyelocytic leukemia (APL) and normal hematopoietic progenitors. FOXC1 mRNA and protein levels were significantly lower in primary marrow samples from 27 APL patients, as compared to samples obtained from 27 patients with other AML subtypes, and 5 normal CD34+ hematopoietic cells. FOXC1 expression significantly increased in APL samples at the time of remission following consolidation treatment. In cell lines overexpressing PML-RARA, and in the NB4 t(15;17)-positive cell line, FOXC1 expression was lower than in other non-APL cell lines, and increased following treatment with all-trans retinoic acid (ATRA), due to functional binding of ATRA to the FOXC1 promoter region. Reduced FOXC1 expression was also associated to DNA hypermethylation of the +354 to +568 FOXC1 region, both in primary APL, and in NB4 cells. Treatment of NB4 cells with decitabine demethylated FOXC1 and upregulated its expression. Our findings indicate that FOXC1 is consistently repressed in APL due to hypermethylation and the presence of the PML-RARA rearrangement. A potential role of hypomethylating treatment in advanced APL remains to be established.

Indexed as

acute promyelocytic leukemiaATRAdecitabineepigenetic regulationforkhead box C1

Identifiers

PMID29137406
PMCPMC5663578
OpenAlexW2755989812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.